Resumen

JALON MONZON, A. et al. Therapeutic effect of Mitomycin C in the immediate postoperatory in patients with low-risk non-muscle-invasive bladder tumours. Actas Urol Esp [online]. 2008, vol.32, n.8, pp.811-820. ISSN 0210-4806.

Introduction: Bladder cancer is a disease with a high prevalence due to its recurrence rate. Transurethral resection of the bladder (TURB) is the treatment in initial stages. Nevertheless, a high percentage of non-muscle-invasive tumors treated will have a recurrence 1-2 years afterwards. Adjuvant quemotherapy or immunotherapy after TURB has been administered in order to decrease the rate of recurrence and to prevent progression. Patients and methods: A prospectived, controlled and randomized study was performed. We included 100 patients with non-muscle-invasive and bladder tumors the low grade. All patients had initially a TURB performed and were randomized to either receive or not a single dose mitomycin C (MMC) in the immediate postoperatory. Results: All low grade tumors was less than 3 cm. Mean follow-up was 26,43±7,65 months. MMC was administered in 49 patients, of these, 67,3% had no recurrence and 32,7% had a non-muscle-invasive recurrence. Of the 51 patients in the non mitomycin, 51% had no recurrence while 47% had a non-muscle-invasive recurrence, and 2% had a muscle-invasive progression. We found significantly differences in time to recurrence among the two groups. Summary: We found a greater time to recurrence in the group of single dose adjuvant MMC being this difference statistically significantly when comparing with the other group.

Palabras clave : Non muscle-invasive; Bladder cancer; Intravesical therapy; Chemotherapy; Mitomycin C.

        · resumen en Español     · texto en Español     · Español ( pdf )